why choose us

First received: January 16, 2025

Clinical Trial: Efficacy of Target - Immunotherapy and XELOX Chemotherapy for Advanced HCC

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Advanced HCC

Study Type: OBSERVATIONAL


Official Title: Efficacy Analysis of the Combined Target - Immunotherapy and XELOX Chemotherapy Regimen in the Treatment of Advanced Hepatocellular Carcinoma.

Brief Summary: In China, primary hepatocellular carcinoma (HCC) has high morbidity and mortality, imposing a heavy burden on the public.Surgical resection is an effective treatment, but as HCC is often latent, less than 30% of patients are suitable for surgery at first diagnosis.So systemic anti-tumor therapy is crucial for advanced HCC.Small-molecule targeted drugs like lenvatinib and sorafenib are NCCN-recommended first-line drugs for advanced HCC.The combination of targeted drugs and immune checkpoint inhibitors can prolong…

Read more